Cingulate Inc.

CING

$5.21

-0.19%

2026-09-04 09:40:35 EDT-$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading ...

Historical Employee Count of CING

Current

Change

+7.69%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	14	10-K	Mar 18, 2026	View
Dec 31, 2024	13	10-K	Mar 27, 2025	View
Dec 31, 2023	13	10-K	Apr 1, 2024	View
Dec 31, 2022	15	10-K	Mar 10, 2023	View
Dec 31, 2021	16	10-K	Mar 28, 2022	View

Supply Chain of CING

Upstream / Downstream / Proxies

Upstream

Bend Bioscience (fka Societal CDMO / CoreRx)Indegene Inc. (Indegene Ltd)NSE:INDGNDr. Vince Clinical Research (DVCR)Third-Party API Suppliers (Unnamed US-based manufacturers)Specialty Excipient & EBL Material SuppliersPharmaceutical Equipment Manufacturers

Downstream

Indegene Inc. (Indegene Ltd)NSE:INDGN

Proxies

Bend BioscienceUnconfirmedIndegene LtdNSE:INDGNSupernus PharmaceuticalsNASDAQ:SUPN Kazia TherapeuticsNASDAQ:KZIA

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer